Iqirvo
1 known investors
IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used with ursodeoxycholic acid (UDCA) or alone for patients who cannot tolerate UDCA. It is marketed by Ipsen Biopharmaceuticals.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Iqirvo do?
- IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used with ursodeoxycholic acid (UDCA) or alone for patients who cannot tolerate UDCA. It is marketed by Ipsen Biopharmaceuticals.
- Who are Iqirvo's investors?
- Iqirvo's investors include HEALTHCARE ROYALTY PARTNERS.